Tepmongkol P, Suphaphongs N, Thansakul A, Jirapanuwat S, Skulchan V, Rojananin S, Chantarakul N
J Med Assoc Thai. 1989 Feb;72(2):82-9.
A total of 35 patients with advanced breast cancer were treated with mitoxantrone, 14 mg/m2 I.V. every 3 weeks. Of these, 27 patients or 78 lesions could be evaluated for response and all 35 patients for toxicity. The overall response rate (CR + PR) was 35 per cent (or CR + PR + SD = 82%), ten lesions achieved a complete response and 17 lesions a partial response. The duration of response varied from a minimum of 2 months to more than 11 months (median = 4 months). Myelosuppression was the dose-limiting toxicity with moderate to severe degree in 19 patients. The most frequent severe degree in 19 patients. The most frequent non-hematologic toxicity was mild grade of nausea and vomiting (67%). No cardiotoxicity was noted in this study after the maximum cumulative dose of mitoxantrone 157.5 mg.
共有35例晚期乳腺癌患者接受米托蒽醌治疗，静脉注射剂量为14mg/m²，每3周一次。其中，27例患者或78个病灶可评估疗效，所有35例患者可评估毒性。总缓解率（完全缓解+部分缓解）为35%（或完全缓解+部分缓解+疾病稳定=82%），10个病灶达到完全缓解，17个病灶部分缓解。缓解持续时间从最短2个月到超过11个月不等（中位数=4个月）。骨髓抑制是剂量限制性毒性，19例患者为中度至重度。19例患者中最常见的严重程度。最常见的非血液学毒性是轻度恶心和呕吐（67%）。在本研究中，米托蒽醌最大累积剂量达157.5mg后未观察到心脏毒性。
